Strong growth, margin pressure; PAT declined despite 17% revenue rise
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Margin guidance intact but qualified; near-term caution warranted. PAT miss signals integration/cost headwinds.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Fortis delivered strong 17% revenue growth and improving EBITDA margins, but profit declined 2.5% YoY—indicating execution stress from ESOP, new unit ramp-up, and drug price controls. Bed expansion strategy is concrete (500+ beds FY27, 2,000 by FY30) but near-term margins remain under pressure.
₹2735 Cr
Revenue · +17.3% YoY₹320.5 Cr
Reported PAT · −2.5% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Hospital revenue 18.6% YoY to ₹2,340 Cr
METQ2 delivered supports this; hospital segment driving growth
Diagnostics 12.2% YoY growth to ₹448 Cr gross
METConfirmed in transcript; slower than hospital growth
EBITDA margins improving to 24.2% vs 23.9% YoY
METOperating EBITDA ₹663 Cr at 24.2% margin reported; YoY expansion
PAT growth 4% to ₹317 Cr pre-exceptional
OVERSTATEDDelivered PAT ₹320.5 Cr shows -2.5% YoY decline; exceptional items and NPM 11.7% suggest margin dilution
500+ beds expected FY27; 2,000 beds total expansion
METSuguna 110 beds + brownfield 200/year mentioned; 2,000-bed target by FY30
Earnings quality
What changed since the last call
Margin guidance qualification
NeutralManagement says 'margin guidance more or less intact' but refrained from FY28 guidance due to drug price control and ramp-up uncertainties. Cautious signal vs prior confidence.
Bed expansion acceleration
UpgradeNow targeting 500+ beds FY27 (vs 400 from prior call) with Suguna acquisition; 2,000-bed multi-year expansion by FY30 with clear mechanisms (greenfield ₹400 Cr, brownfield ₹3,500 Cr CAPEX committed)
Diagnostics growth guidance reiterated
MaintainedHeld 12-13% growth guidance for FY27; Q2 achieved 12.2%, wellness segment now 15% of revenue (vs 13% prior year), B2C mix 54% (vs 52%)
The Q&A
Analysts pressed hard on margins (Dhvani Shah, DSP; Neha Manpuria, BOFA), occupancy bottlenecks (Abdulkader Puranwala, ICICI), and acquisition strategy (Saion Mukherjee, Nomura). Management held ground on strategy but candidly conceded near-term margin uncertainties and drug price control impact, declining specific FY28 guidance.
Bed expansion greenfield timing — Neha Manpuria, Bank of America
Partial400-bed agreement with Seth Sunder Lal Jain Charitable Eye Hospital Society; partnership model; capex ₹3,500 Cr committed over brownfield/greenfield; 3-4 year timeline. One greenfield ₹400 Cr Delhi hospital coming over next 4 years.
Bangalore occupancy ramp-up — Abdulkader Puranwala, ICICI Securities
PartialSuguna is community/secondary care hospital; serves micro-market cluster alongside larger units. Different formats required for different patient profiles. Occupancy will improve; financially performing well. No near-term margin drag.
FMRI progress and profitability — Neha Manpuria, Bank of America
PartialNew block waiting for final approvals; should commission soon. Attracted good clinical talent in last months. Radiation oncology facility expected by February (Q4 FY27). Currently producing low-double-digit EBITDA; expect jump when oncology added.
Drug price control impact — Dhvani Shah, DSP Mutual Fund
DodgedVery difficult to assess exact quantum; circular very recent. One-third of oncology revenue exposed; some drugs profitable, some not. Calculating impact; will not give specific margin guidance until clarity. Expect margin flattish end-FY27, TBD for FY28.
Margin guidance and FY28 outlook — Neha Manpuria, Bank of America
DodgedMargin guidance 'more or less remains intact.' Challenges exist: FMRI OP pending, Manesar and People Tree in ramp-up, drug price controls uncertain. Will not comment on FY28 margin now; refrain from guidance due to uncertainty. Expect flattish EBITDA margin end-FY27.
Diagnostics growth bridging peer gap — Shyam Srinivasan, Goldman Sachs
PartialWellness now 15% of revenue (up from 13%), specialized growing. B2C up to 54% (from 52%). Focused on deep-market penetration, more centers, mid-teens growth target. Volume growth will improve with initiatives in specialized testing and B2C expansion.
IHH stake increase constraint — Atul Minocha, Independent Investor
AnsweredSupreme Court FY23 decision cleared IHH to increase stake. Forensic audit is separate; no constraint to IHH stake. Audit ordered by court, timeline 6 months. Constraint is IHH's decision on capex/dividend needs, not legal.
Gleaneagles O&M footprint and margin — Damayanti Kurai, HSBC
AnsweredOne year to stabilize operations; focused on recruiting doctors, facility upgrades, IT systems. Operations nearly flat; expect improvement from next year. Stabilization first, margin recovery later.
Guidance
Diagnostics FY27: 12-13% growth (reiterated)
MediumQ2 achieved 12.2%. Wellness acceleration and specialized testing expansion supporting mid-teens long-term, but near-term held at 12-13%.
Hospital bed expansion: 500+ beds FY27; 2,000 beds by FY30
HighSuguna 110 beds live; brownfield ~200 beds/year for next 2 years; greenfield ₹400 Cr Delhi hospital in pipeline. Committed CAPEX ₹3,500 Cr.
Hospital EBITDA 25% target FY28 (post-ESOP offset) — maintained
LowManagement says 'margin guidance more or less intact' but heavily qualified. New units (Manesar, People Tree) in ramp-up; FMRI OP pending. Refrained from FY28 margin guidance.
FY27 year-end EBITDA margin expected flattish
MediumCurrently 24.2% in Q2; Vivek said expect EBITDA margin 'flattish' end-FY27 due to ramp-up costs and drug price control uncertainties.
Committed CAPEX ₹3,500 Cr for brownfield/greenfield expansion
HighSpread over 3-3.5 years; includes Suguna (₹270 Cr), greenfield Delhi (₹400 Cr), brownfield facilities at Mohali, Shalimar Bagh, and others.
Risks the call surfaced
Regulatory & pricing
High137 oncology drugs under price cap; one-third of oncology revenue (~₹60-70 Cr) exposed. Impact magnitude unquantified. Management acknowledged 'very difficult' to assess.
Execution
HighFMRI flagship ₹200 Cr project not yet operationalized; Manesar and People Tree still in ramp-up with margin drag. Bangalore acquisition occupancy only 63%.
Operational
HighPAT declined 2.5% YoY despite 17% revenue growth. ESOP (₹140 Cr FY27) masking underlying margins. Drug price controls, ramp-up costs, and cost inflation pressuring profitability.
Financial
MediumNet debt ₹2,188 Cr (0.87x EBITDA). Committed CAPEX ₹3,500 Cr over 3-3.5 years requires debt/internal accrual. Risks if revenue growth or margins miss guidance.
Legal
LowForensic audit ordered by court; 6-month timeline. IHH stake increase possible but pending legal clarity. Overhang could delay strategic decisions.
Management
Score 7/10. Clear and candid on challenges. Refrained from speculative guidance (FY28 margin) pending drug price control clarity. Direct answers on most questions; some deflection on oncology margin impact timing. Mixed. Revenue growth 17.3% strong; EBITDA margin +30 bps YoY. But PAT flat/down and new unit ramp-up delayed vs history suggest execution friction. FMRI OP still pending.
1 · Q3 FY27
FMRI operational profitability; oncology impact clarity from drug price controls
2 · Q4 FY27
Manesar radiation oncology facility commissioning; People Tree ramp-up progress
3 · FY28
Two brownfield expansions (Mohali, Shalimar Bagh) completion; bed expansion to 2,000+ units
Bed expansion strategy is concrete (500+ beds FY27, 2,000 by FY30) but near-term margins remain under pressure.
Informational and educational content only. Not investment advice.